Sublingual immunotherapy and allergic rhinitis

Current Allergy and Asthma Reports

Volumn 8, Issue 2, 2008, Pages 102-110

  Cox, Linda S ^a  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALNUS GLUTINOSA EXTRACT; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; BETULA VERRUCOSA EXTRACT; CAT DANDER EXTRACT; CORYLUS AVELLANA EXTRACT; GRASS POLLEN EXTRACT; GRAZAX; ORALAIR; PLACEBO; PLANT EXTRACT; STALLERGEN; STALORAL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ALDER; ALLERGIC RHINITIS; ALNUS GLUTINOSA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BETULA VERRUCOSA; BIOLOGICAL THERAPY; BIRCH; BURNING SENSATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORYLUS AVELLANA; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLUSHING; GASTROINTESTINAL DISEASE; HAZELNUT; HEADACHE; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MONOTHERAPY; MOUTH DISEASE; ORAL PRURITUS; PALATE DISEASE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARYNX DISEASE; POLLEN ALLERGY; PRURITUS; RELAPSE; REVIEW; SIDE EFFECT; SKIN SENSITIZATION; SPECIFIC ALLERGEN IMMUNOTHERAPY; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ADMINISTRATION, SUBLINGUAL; ANTIGENS, PLANT; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG APPROVAL; HUMANS; IMMUNOTHERAPY; PLANT EXTRACTS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; UNITED STATES;

EID: 42149163526     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0019-5     Document Type: Review

References (50)

1. Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
2. Eng PA, Borer-Reinhold M, Heijnen IA, et al.: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198-201.
3. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001, 31:1295-1302.
4. Polosa R, Al-Delaimy WK, Russo C, et al.: Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005, 6:153.
5. Des Roches A, Paradis L, Menardo JL, et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450-453.
6. Jacobsen L, Niggemann B, Dreborg S, et al.: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943-948.
7. Bernstein JA: Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol 2004, 18:151-164.
8. Ariano R, Berto P, Tracci D, et al.: Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006, 27:159-163.
9. Hankin CS, Cox L, Wang Z, et al.: Allergy immunotherapy practice patterns and associated outcomes of care. J Allergy Clin Immunol 2007, 199:S159.
10. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group [no authors listed]. N Engl J Med 2000, 343:1054-1063.
11. Guilbert TW, Morgan WJ, Zeiger RS, et al.: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006, 354:1985-1997.
12. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology: Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007, 120:S25-S85.
13. Cox LS, Linnemann DL, Nolte H, et al.: Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117:1021-1035.
14. Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E, et al.: Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 2007, 62:810-817. [Published erratum appears in Allergy 2007, 62:1100.]
15. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A: A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993, 92:229-236.
16. Didier A, Malling HJ, Worm M, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338-1345.
17. Durham S, Yang W, Pedersen M, et al.: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802-809.
18. Dahl R, Kapp A, Colombo G, et al.: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118:434-440.
19. Dahl, R, Stender A, Rak S: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006, 61:185-190.
20. Durham SR, Riis B: Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007, 62:954-957.
21. Dahl R, Kapp A, Colombo G, et al.: Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2007, Epub ahead of print.
22. Frew AJ, Powell RJ, Corrigan CJ, et al.: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319-325.
23. Valovirta E, Jacobsen L, Ljorring C, et al.: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177-1183.
24. Savolainen J, Jacobsen L, Valovirta E: Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006, 61:1184-1190.
25. Arbes SJ, Jr, Gergen PJ, Elliott L, et al.: Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005, 116:377-383.
26. Marogna M, Spadolini I, Massolo A, et al.: Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007, 98:274-280.
27. Khinchi MS, Poulsen LK, Carat F, et al.: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004, 59:45-53.
28. Wilson DR, Torres LI, Durham SR: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003, 2:CD002893.
29. Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1:CD001936.
30. Polosa R, Li Gotti F, Mangano G, et al.: Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004, 59:1224-1228.
31. Di Rienzo V, Marcucci F, Puccinelli P, et al.: Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003, 33:206-210.
32. Novembre E, Galli E, Landi F, et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-857.
33. Des Roches A, Paradis L, Knani J, et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996, 51:430-433.
34. Cox L, Cohn JR: Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol 2007, 98:416-426.
35. Marogna M, Bruno M, Massolo A, et al.: Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 2007, 142:70-78.
36. Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990, 18:277-284.
37. Rolinck-Werninghaus C, Wolf H, Liebke C, et al.: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285-1293.
38. Stewart GE 2nd, Lockey RF: Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992, 90(4 Pt 1):567-578.
39. Van Metre TE, Adkinson NF, Amodio FJ, et al.: A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982, 69:181-193.
40. Amin HS, Liss GM, Bernstein DI: Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006, 117:169-175.
41. Bernstein DI, Wanner M, Borish L, et al.: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004, 113:1129-1136.
42. Reid MJ, Lockey RF, Turkeltaub PC, et al.: Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993, 92(1 Pt 1):6-15.
43. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987, 79:660-677.
44. Antico A, Pagani M, Crema A: Anaphylaxis by latex sublingual immunotherapy. Allergy 2006, 61:1236-1237.
45. Eifan AO, Keles S, Bahceciler NN, et al.: Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007, 62:567-568.
46. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA: Anaphylaxis to sublingual immunotherapy. Allergy 2006, 61:1235.
47. Bachert C, Vestenbaek U, Christensen J, et al.: Cost-effectiveness of grass allergen tablet (GRAZAX(R)) for the prevention of seasonal grass pollen induced rhinoconjunctvitis: a Northern European perspective. Clin Exp Allergy 2007, 37:772-779.
48. Andre C, Perrin-Fayolle M, Grosclaude M, et al.: A double-blind placebo-controlled evaluation of sublingual. immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003, 131:111-118.
49. Marcucci F, Sensi L, Di Cara G, et al.: Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005, 60:952-956.
50. Bordignon V, Burastero SE: Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006, 97:158-163.